Evommune, Inc.
NYSE:EVMNBiotechnology
-$0.17 today
- Market cap
- $284.49M
- Beta
- 0.10
- P/E (TTM)
- -9.1
- EPS (TTM)
- -$2.26
Volume 0.60M
Average 0.38M
EVMN Intangible Assets
Identifiable non-physical assets such as patents, trademarks, licenses, and customer relationships.
Evommune, Inc.NYSE: EVMN
Intangible Assets · Q1 FY2026 · quarter ended Mar 2026
Intangible assets remains negative
Q1 FY2026 intangible assets was $1.39M, compared with $0 a year earlier.
Context
- Intangible assets amounted to 0.4% of total assets at the end of Q1 FY2026, up 0.4 pp from a year earlier.
- Intangible assets increased in 0 of the last 2 fiscal years.
- FY2025 was the highest annual figure in the 3 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Intangible Assets history
USD · from the balance sheet
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Intangible Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
Intangible Assets vs competitors
How EVMN compares with its peers on the latest reported figures
- EVMN's Mar 2026 intangible assets of $1.39M is the 5th highest of the 10 companies compared; the peer median is $0.
- Intangible assets amounts to 0.4% of total assets for EVMN, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
FTREFortrea Holdings Inc. | Jun 2026 | $586.8M | -10.3% | -8.9% | 21.6% |
| Sep 2026 | $431.03M | +30754.0% | +271.3% | 36.6% | |
| Jun 2026 | $209.24M | -16.3% | +6.2% | 9.6% | |
| Mar 2026 | $119.12M | -11.7% | -9.2% | 40.6% | |
EVMNEvommune, Inc. | Mar 2026 | $1.39M | — | — | 0.4% |
CLYMClimb Bio, Inc. | Mar 2026 | $0 | — | — | 0.0% |
ARTVArtiva Biotherapeutics, Inc. | Mar 2026 | $0 | — | — | 0.0% |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding EVMN) | $0 | -11.0% | -1.4% | 0.0% | |
Competitors are the stored peer set for EVMN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Evommune, Inc.
NYSE:EVMN
Intrinsic Alpha fair value
Locked
Current Price
$6.88
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.